Shopping Cart
Total:

$0.00

Items:

0

Checkout View Cart
Your cart is empty
Keep Shopping

Off-Label Drug Proves Its Mettle in Relapsing Multiple Sclerosis



(MedPage Today) — Off-label rituximab was noninferior to ocrelizumab (Ocrevus) in people with newly diagnosed relapsing multiple sclerosis (MS) and recent disease activity, the phase III OVERLORD-MS trial showed.
At 2 years, the estimated probability…



Source link

0
Show Comments (0) Hide Comments (0)
0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Oldest
Newest Most Voted
Inline Feedbacks
View all comments